PCD Research’s Post

Exciting Advances in Rheumatic Disease Treatment! Recent studies are paving the way for a future where reliance on traditional glucocorticoid (GC) therapies could be significantly reduced, minimizing their notorious side effects. 🔬 Innovative Research: 11β-HSD1 Inhibitors like SPI-62 and AZD4017 have shown promising results in reducing GC side effects such as insulin resistance and bone health issues. Sarilumab and Tocilizumab, IL-6 receptor blockers, have demonstrated efficacy in allowing faster and more controlled GC tapering with fewer relapses in conditions like PMR and GCA. 🩺 These emerging treatments not only enhance disease management but also improve patient quality of life by reducing the adverse effects associated with long-term steroid use. 🚀 As these clinical trials progress, we are hopeful for a future with more personalized and safer therapeutic options for rheumatic diseases. Stay tuned for more updates on these groundbreaking advancements! 💡 #Rheumatology #MedicalResearch #PatientCare #InnovativeMedicine #HealthcareTransformation #Glucocorticoids #SteroidSparing #ClinicalTrials

How are biotechs raising the bar for fatal liver disease treatments? 🧬 Acute on-chronic liver failure is a major healthcare issue with high unmet needs for patients, and a massive burden for healthcare systems. 🩺 French biopharma Genfit aims to take on rare, life-threatening liver diseases with a range of therapeutic targets. 🎯 💬 Labiotech spoke to GENFIT’s CSO Dean Hum about what treatments are on the way to treat the debilitating condition. 💊 🎧 Tune into the latest episode of the Beyond Biotech Podcast to find out about novel therapies addressing liver disease! 👇 https://lnkd.in/d59ENPAK #BeyondBiotechPodcast #liverdisease #biotechinnovation #healthcaresolutions #rarediseases #medicalresearch

Are you attending the European Congress on Obesity in May? Don't miss the chance to meet #Perspectum's Pharma Solutions team! Book and appointment with one of our team members to learn about our leadership in using imaging to identify and monitor multi-organ disease in clincal trials. Let us help you revolutionize your approach to clinical trials in obesity-related liver diseases. See you there! #ECO24 #clinicaltrials

A recent article in The New York Times highlights a groundbreaking perspective on #inflammation as a key driver of various diseases, from heart disease to dementia. As the understanding of inflammation evolves, so does our approach to managing it. At NodThera, we are at the forefront of this transformation. Our work focuses on developing innovative therapeutics that precisely target #NLRP3 #inflammasome to tackle chronic conditions without compromising the body's essential defense mechanisms. We aim to bring a new class of anti-inflammatory drugs to market that can address the “silent” yet detrimental effects of chronic inflammation while preserving the balance necessary for overall health. The future of medicine is not about eliminating inflammation but managing it intelligently to enhance patient outcomes. We're excited to be part of this journey, leveraging our cutting-edge research to develop novel therapies that can potentially transform how we treat a myriad of conditions linked to chronic inflammation. Read the full NYT article here: https://lnkd.in/dN_irKBy

LIVERFASt provides all the 3 critical components of NASH especially an equivalent to ballooning which can be priceless in initial diagnosis to make treatment decisions and for serial monitoring (the latter needing some validation) as pharmacotherapy takes on the new chapter of this science. The burden of cost of missing advanced liver fibrosis in a disease which is endemic to almost all populations is tremendous The burden of false positives when combining NITs is also tremendous as it can lead to more unnecessary liver biopsies which are invasive and associated with significant complication rate. Combination of LIVERFASt and LSM outperforms Fib4 and LSM across the spectrum of liver fibrosis. LIVERFASt can serve as both a screening and a diagnostic test in patients where there is a high prevalence of the disease and potentially minimize the false negative and false positive rates thereby reducing cost and helping diagnose disease accurately. #liverfast #noninvasivetesting 

📈💡 Follow along this week as we highlight #TargetLD, the largest #LiverDisease registry with over 400,000+ regionally distributed patients suffering from chronic liver diseases like #NASH, #HBV, #PBC, #HCC, and #Cirrhosis. Our collaboration with the American Association for the Study of Liver Diseases (AASLD), network of 50+ highly engaged sites, and 25+ #ClinicalInvestigators underscores the importance of working in unity to drive cutting-edge research and data-driven insights that improve the lives of patients suffering from liver diseases. To learn more about TARGET-LD’s potential to accelerate drug development programs and #PatientCare, click the link: https://lnkd.in/g8SVJQWk #TargetRWE #Hepatology #NASHResearch #LiverHealth #RealWorldData #RealWorldEvidence #DrugDevelopment

Rare Disease Day serves as a reminder of the obstacles faced by the 300 million individuals worldwide affected by rare diseases. Did you know that 1 in 5 cancers fall under rare diseases? The survival rates for rare cancer patients are alarmingly lower compared to those with more common forms. Shockingly, over 90% of rare diseases lack effective treatments, posing challenges for healthcare providers, researchers and patients. InnoGI Technologies is dedicated to helping overcome challenges in the development of these much-needed drugs. Through our SurroGUT™ platform solutions, such as our TIM systems, we can mirror Disease conditions that are GI-related dysfunctions in the human GI tract. This approach can potentially aid in comprehending the behavior of candidate treatments for rare diseases while helping to reduce clinical trial risks. While we recognize there's still much more progress to be made, we support Rare Disease Day, championing equal healthcare access and treatment development. #InnoGITechnologies #RareDiseaseDay #HealthcareAccess

ALPCO’s new infographic highlights the American Gastroenterological Association (AGA)’s clinical practice guidelines, particularly focusing on the use of a biomarker and symptom-based monitoring strategy. It clarifies the significance of fecal calprotectin and C-reactive protein (CRP) levels in assessing disease activity and guiding the need for endoscopic evaluation.      Learn more here: bit.ly/3V7Xmvx #AGA #AGAGuidelines #Biomarkers #CrohnsDisease #CrohnsResearch #CrohnsAwareness #CrohnsManagement #CD #CDResearch #CDAwareness #CDManagement

I’m very glad to share the publication of the first prospective, longitudinal, multicenter study evaluating the efficacy and safety profile of Upadacitinib in the treatment of Rheumatoid Arthritis (RA) in a real-life context. This groundbreaking research, involving RA patients across three Italian centers, provides valuable clinimetric and ultrasonographic data, highlighting significant improvements in disease activity and ultrasonographic findings over time. Key findings include: • Significant improvements in Disease Activity Score (DAS28-CRP) and Simplified Clinical Disease Activity Index (SDAI), as well as in synovial hypertrophy and power Doppler signals. • A notable association between concomitant conventional synthetic DMARDs therapy at baseline and the lack of improvement in certain outcomes, whereas increased baseline ESR or CRP levels were predictive of significant improvement. • Importantly, no adverse events such as deep venous thrombosis, pulmonary embolism, or herpes zoster virus infection were reported, underscoring Upadacitinib’s favorable safety profile. This study underscores the importance of personalized treatment strategies in managing RA and reinforces Upadacitinib’s role as a highly effective and safe option for patients. We look forward to continuing our research to further understand and improve the lives of those affected by RA. Special Thanks to Caterina Baldi and all Collegues for the wonderful work Take a look here 👉🏻 urly.it/3-d08 #RheumatoidArthritis #Upadacitinib #ClinicalResearch #InnovationInHealthcare #PersonalizedMedicine

Patient-Centric Care: Unlocking the Full Potential of Emerging Retinal Disease Therapies Retinal disease treatment is evolving rapidly, driven by an aging population with 11 million Americans affected by age-related macular degeneration (AMD). As the elderly population grows, the prevalence of retinal diseases like wet AMD and geographic atrophy (GA) is expected to double by 2050, emphasizing the urgent need for innovative treatments that prioritize patient-centric care. The clinical trial pipeline for retinal diseases is both deep and broad, with numerous therapies in development aimed at meeting the unique needs of patients. By focusing on patient outcomes, these treatments offer hope for slowing disease progression and restoring vision, making patient engagement a critical factor in treatment success. Izervay (avacincaptad pegol) offers a breakthrough for GA, reducing disease progression by 27% at 12 months and addressing an unmet need for patients. Vabysmo (faricimab), with its dual-targeting approach to VEGF and Ang-2, has revolutionized wet AMD and diabetic macular edema (DME) treatment, offering 8-16 week dosing flexibility and generating $2.1 billion in US sales. Additionally, OPT-302 is emerging as a promising option for wet AMD, with clinical trials showing significant improvements in combination with standard therapies like aflibercept. #RetinalDisease #PatientCentricCare #WetAMD #GeographicAtrophy #Izervay #Vabysmo #OPT302 #VisionRestoration #ClinicalTrials #EyeCareInnovation